Clicky

Lucid Diagnostics Inc.(LUCD)

Description: Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.


Keywords: Cancer Gastroenterology Esophageal Cancer Digestive Diseases Esophagus Gastroesophageal Reflux Disease Barrett's Esophagus

Home Page: www.luciddx.com

LUCD Technical Analysis

One Grand Central Place
New York, NY 10165
United States
Phone: 212 949 4319


Officers

Name Title
Dr. Lishan Aklog M.D. Chairman & CEO
Mr. Dennis M. McGrath CPA CFO, Pres & Sec.
Dr. Sanford D. Markowitz M.D., Ph.D. Cofounder & Strategic Advisor, Member of the Medical Advisor Board
Dr. Joseph Willis M.D. Cofounder, Strategic Advisor & Member of Medical Advisory Board
Dr. Amitabh Chak M.D. Cofounder, Strategic Advisor & Member of Medical Advisory Board
Mr. Shaun M. O'Neill M.B.A. Exec. VP & COO
Richard D. Yazbeck Chief Technology Officer
Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer
Mr. Adrian K. Miller VP of Investor Relations
Dr. Brian J. deGuzman M.D. Chief Compliance Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3721
Price-to-Sales TTM: 112.8254
IPO Date: 2021-10-14
Fiscal Year End: December
Full Time Employees: 0
Back to stocks